Related references
Note: Only part of the references are listed.Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion.
Sam S. Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T. Powles et al.
ANNALS OF ONCOLOGY (2022)
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
Marko Babjuk et al.
EUROPEAN UROLOGY (2022)
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
J. Alfred Witjes et al.
EUROPEAN UROLOGY (2021)
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A. Boorjian et al.
LANCET ONCOLOGY (2021)
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt et al.
LANCET ONCOLOGY (2021)
Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).
Peter C. Black et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
Arjun Balar et al.
LANCET ONCOLOGY (2021)
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
D. F. Bajorin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Emerging treatments for bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer
Hyung Suk Kim et al.
INVESTIGATIVE AND CLINICAL UROLOGY (2021)
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
Ryan L. Steinberg et al.
JOURNAL OF UROLOGY (2020)
Heated Intravesical Chemotherapy Biology and Clinical Utility
Wei Phin Tan et al.
UROLOGIC CLINICS OF NORTH AMERICA (2020)
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence SWOG S0337 Randomized Clinical Trial
Edward M. Messing et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
PHASE 3 STUDY OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER: INITIAL RESULTS
Rian Dickstein et al.
JOURNAL OF UROLOGY (2018)
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
Noah M. Hahn et al.
CLINICAL CANCER RESEARCH (2017)
Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
Niv Milbar et al.
BLADDER CANCER (2017)
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
Sam S. Chang et al.
JOURNAL OF UROLOGY (2016)
Sequential Combination of Mitomycin C Plus Bacillus Calmette-Guerin (BCG) Is More Effective but More Toxic Than BCG Alone in Patients with Non-Muscle-invasive Bladder Cancer in Intermediate-and High-risk Patients: Final Outcome of CUETO 93009, a Randomized Prospective Trial
Eduardo Solsona et al.
EUROPEAN UROLOGY (2015)
Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public Workshop
Jonathan P. Jarow et al.
UROLOGY (2014)
PD-L1 (B7-H1) expression by urothelial carcinoma of bladder and BCG-induced granulomata - Associations with localized stage progression
Brant A. Inman et al.
CANCER (2007)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
Management of stage T1 tumors of the bladder: International consensus panel
AM Nieder et al.
UROLOGY (2005)
Bacillus Calmete-Guerin plus interferon-α2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity
JS Lam et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2003)